CN113226377B - 包含依特那斯汀衍生物的抗体药物共轭物 - Google Patents

包含依特那斯汀衍生物的抗体药物共轭物 Download PDF

Info

Publication number
CN113226377B
CN113226377B CN201980084790.7A CN201980084790A CN113226377B CN 113226377 B CN113226377 B CN 113226377B CN 201980084790 A CN201980084790 A CN 201980084790A CN 113226377 B CN113226377 B CN 113226377B
Authority
CN
China
Prior art keywords
group
substituted
alkylene
unsubstituted
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980084790.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226377A (zh
Inventor
马里亚·德尔·卡门·库瓦斯马昌特
A·弗兰切斯凯索洛索
阿方索·拉托雷洛萨诺
瓦伦丁·马丁内斯巴拉萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN113226377A publication Critical patent/CN113226377A/zh
Application granted granted Critical
Publication of CN113226377B publication Critical patent/CN113226377B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980084790.7A 2018-10-25 2019-10-25 包含依特那斯汀衍生物的抗体药物共轭物 Active CN113226377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382759.1 2018-10-25
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (2)

Publication Number Publication Date
CN113226377A CN113226377A (zh) 2021-08-06
CN113226377B true CN113226377B (zh) 2022-10-18

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980084790.7A Active CN113226377B (zh) 2018-10-25 2019-10-25 包含依特那斯汀衍生物的抗体药物共轭物

Country Status (37)

Country Link
US (1) US12653900B2 (cg-RX-API-DMAC10.html)
EP (1) EP3870234B1 (cg-RX-API-DMAC10.html)
JP (1) JP7629400B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210086669A (cg-RX-API-DMAC10.html)
CN (1) CN113226377B (cg-RX-API-DMAC10.html)
AR (1) AR117657A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019368687B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007718A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117268C (cg-RX-API-DMAC10.html)
CL (1) CL2021001039A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021006838A2 (cg-RX-API-DMAC10.html)
DK (1) DK3870234T3 (cg-RX-API-DMAC10.html)
EA (1) EA202191131A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21035414A (cg-RX-API-DMAC10.html)
ES (1) ES2939494T3 (cg-RX-API-DMAC10.html)
FI (1) FI3870234T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20230275T1 (cg-RX-API-DMAC10.html)
HU (1) HUE061606T2 (cg-RX-API-DMAC10.html)
IL (1) IL282577B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20210083B1 (cg-RX-API-DMAC10.html)
LT (1) LT3870234T (cg-RX-API-DMAC10.html)
MA (1) MA59661B1 (cg-RX-API-DMAC10.html)
MD (1) MD3870234T2 (cg-RX-API-DMAC10.html)
MX (1) MX2021004746A (cg-RX-API-DMAC10.html)
MY (1) MY206221A (cg-RX-API-DMAC10.html)
PH (1) PH12021550930A1 (cg-RX-API-DMAC10.html)
PL (1) PL3870234T3 (cg-RX-API-DMAC10.html)
PT (1) PT3870234T (cg-RX-API-DMAC10.html)
RS (1) RS64068B1 (cg-RX-API-DMAC10.html)
SA (1) SA521421855B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202104154WA (cg-RX-API-DMAC10.html)
SI (1) SI3870234T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300076T1 (cg-RX-API-DMAC10.html)
TW (1) TWI824043B (cg-RX-API-DMAC10.html)
UA (1) UA129803C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020084115A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202103478B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3615544T (lt) * 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
IL308389A (en) * 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228597A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin
WO2026098196A1 (zh) * 2024-11-08 2026-05-15 映恩生物科技(上海)有限公司 海鞘素类化合物、其偶联物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564822A (zh) * 2001-08-07 2005-01-12 法马马有限公司 抗肿瘤类似物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2005281359A1 (en) 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
WO2011147828A1 (en) 2010-05-25 2011-12-01 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
IT201700041639A1 (it) 2017-04-13 2018-10-13 M C Automations S R L Dispositivo di trasferimento per macchine incartatrici di prodotti dolciari
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CR20220581A (es) * 2020-04-21 2023-01-09 Pharma Mar Sa Conjugados de anticuerpos de fármacos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564822A (zh) * 2001-08-07 2005-01-12 法马马有限公司 抗肿瘤类似物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antibody-Drug Conjugates for Cancer Therapy:Chemistry to Clinical Implications;Nirnoy Dan等;《Pharmaceuticals》;20180409;第1-22页 *
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study;E. Calvo等;《Annals of Oncology》;20170714;第28卷;第2559-2566页 *
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity;JFM Leal等;《British Journal of Pharmacology》;20101231;第161卷;第1099-1110页 *

Also Published As

Publication number Publication date
US12653900B2 (en) 2026-06-16
ZA202103478B (en) 2022-12-21
MA59661B1 (fr) 2023-03-31
HRP20230275T1 (hr) 2023-04-28
BR112021007718A2 (pt) 2021-08-10
SG11202104154WA (en) 2021-05-28
US20230012681A1 (en) 2023-01-19
ES2939494T3 (es) 2023-04-24
AU2019368687B2 (en) 2025-10-23
EP3870234A1 (en) 2021-09-01
ECSP21035414A (es) 2021-06-30
AR117657A1 (es) 2021-08-25
LT3870234T (lt) 2023-03-27
FI3870234T3 (fi) 2023-03-23
JOP20210083A1 (ar) 2023-01-30
CO2021006838A2 (es) 2021-06-10
SMT202300076T1 (it) 2023-05-12
JP2022512830A (ja) 2022-02-07
TWI824043B (zh) 2023-12-01
RS64068B1 (sr) 2023-04-28
JOP20210083B1 (ar) 2024-12-22
KR20210086669A (ko) 2021-07-08
IL282577B2 (en) 2023-10-01
TW202034957A (zh) 2020-10-01
MY206221A (en) 2024-12-04
AU2019368687A1 (en) 2021-06-10
MX2021004746A (es) 2021-08-24
CA3117268A1 (en) 2020-04-30
MD3870234T2 (ro) 2023-05-31
SI3870234T1 (sl) 2023-06-30
CA3117268C (en) 2023-11-21
EA202191131A1 (ru) 2021-10-15
UA129803C2 (uk) 2025-08-06
HUE061606T2 (hu) 2023-07-28
EP3870234B1 (en) 2022-12-21
IL282577A (en) 2021-06-30
WO2020084115A1 (en) 2020-04-30
PT3870234T (pt) 2023-03-06
JP7629400B2 (ja) 2025-02-13
DK3870234T3 (da) 2023-03-20
SA521421855B1 (ar) 2023-12-11
CN113226377A (zh) 2021-08-06
PL3870234T3 (pl) 2023-04-24
PH12021550930A1 (en) 2021-11-22
IL282577B1 (en) 2023-06-01
CL2021001039A1 (es) 2021-10-01

Similar Documents

Publication Publication Date Title
ES2939494T3 (es) Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina
RU2669812C2 (ru) Конъюгаты антитела с лекарственным средством
CN115427081B (zh) 药物抗体共轭物
US12011485B2 (en) Sulfomaleimide-based linkers and corresponding conjugates
CN114615999B (zh) 药物抗体偶联物
EA046742B1 (ru) Конъюгаты антитело-лекарственное средство, содежащие производные эктеинасцидина
HK40053316A (en) Antibody drug conjugates comprising ecteinascidin derivatives
HK40053316B (en) Antibody drug conjugates comprising ecteinascidin derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant